ライフサイエンスコーパス: Thailand

1 perties of stingless bee honey from SE Asia (Thailand).

2 caragua, Panama, Philippines, Sri Lanka, and Thailand).

3 ive hospital clinics in Uganda, the USA, and Thailand.

4 V-negative persons conducted in Botswana and Thailand.

5 rging artemisinin resistance in northwestern Thailand.

6 ates, Europe, Australia, Canada, Israel, and Thailand.

7 treatment of MERS-CoV infections imported to Thailand.

8 ant TB are major challenges of TB control in Thailand.

9 ultidrug resistant A. baumannii strains from Thailand.

10 om HIV-uninfected participants from Bangkok, Thailand.

11 odia and 15 of 15 isolates from northeastern Thailand.

12 are for treatment of HCV genotype 1 and 6 in Thailand.

13 Z) in imported Pangasius catfish products in Thailand.

14 ai language-grown in four major provinces in Thailand.

15 ted in Puerto Rico, Colombia, Singapore, and Thailand.

16 swab samples collected at Siriraj Hospital, Thailand.

17 a vaccine in this HIV-infected population in Thailand.

18 sent from 8859 children in 364 hospitals in Thailand.

19 pertussis (Tdap) vaccine during pregnancy in Thailand.

20 an environmental bacillus found in northeast Thailand.

21 ve survival of colorectal cancer patients in Thailand.

22 ment and private hospitals from all parts of Thailand.

23 udy for DENV transmission in Kamphaeng Phet, Thailand.

24 enza vaccine in HIV-infected men in Bangkok, Thailand.

25 hildren with HIV after 7 years of rollout in Thailand.

26 nly chronic hepatitis C genotypes 2 and 3 in Thailand.

27 kok, and the Shoklo Malaria Research Unit in Thailand.

28 ected from 3 gardens in Nonthaburi province, Thailand.

29 account for 30-50 % of all HCV infection in Thailand.

30 ll subsets in dengue patients from India and Thailand.

31 egetables and fruits collected from Southern Thailand.

32 (Bp), the causative agent of melioidosis in Thailand.

33 hern Africa and men who have sex with men in Thailand.

34 inical trial done at three clinical sites in Thailand.

35 ns of China and South Korea, and possibly in Thailand.

36 America, and as low as 7-9% in Mongolia and Thailand.

37 live-attenuated influenza vaccine (LAIV) in Thailand.

38 he village boundary into a natural forest in Thailand.

39 seudomallei, a common cause of septicemia in Thailand.

40 parameterized using country-level data from Thailand.

41 al centers in the United States, Europe, and Thailand.

42 ginger plant in the tropical dry forests of Thailand.

43 consequence of the demographic transition in Thailand.

44 135) and P falciparum (n = 77) isolates from Thailand.

45 49% and ranged from 27% in Brazil to 78% in Thailand.

46 ross seven sites in Brazil, Peru, India, and Thailand.

47 s were seen in Malaysia, the Philippines, or Thailand.

48 enic mice and in seropositive individuals in Thailand.

49 inic at Chiang Mai University in Chiang Mai, Thailand.

50 nvironmental risk factors for oral clefts in Thailand.

51 s infection from Malaysia, South Africa, and Thailand.

52 rEP among men who have sex with men (MSM) in Thailand.

53 c surveillance site of 100 villages in rural Thailand.

54 osa MDR clinical isolates from a hospital in Thailand.

55 al isolate of Burkholderia pseudomallei from Thailand.

56 cohort of pregnant women in India, Peru, and Thailand.

57 a high-transmission setting in a hospital in Thailand.

58 ns from 858 hospitals across 77 provinces in Thailand.

59 uding a clade of Manila-like strain-types in Thailand.

60 d the long-term circulation of Zika virus in Thailand.

61 ng with a widespread distribution throughout Thailand.

62 9% of acutely-treated HIV-infected adults in Thailand.

63 pertussis (Tdap)-vaccine during pregnancy in Thailand.

64 tudy in two tertiary hospitals in Khon Kaen, Thailand.

65 r treating patients with retinal diseases in Thailand.

66 he real-life effectiveness of IVB and IVR in Thailand.

67 ory of carbon stocks at a coastal setting in Thailand.

68 is recommended in Australia, and 20 weeks in Thailand.

69 ngo, Kenya, Nigeria, South Africa, Peru, and Thailand.

70 i Red Cross AIDS Research Centre in Bangkok, Thailand.

71 was conducted at Siriraj Hospital, Bangkok, Thailand.

72 s (Canada [11], Argentina [1], Peru [1], and Thailand [1]).

73 lower than a virulent Asian-lineage H5N1 (A/Thailand/16/2004) virus.

74 ections in schoolchildren in Kamphaeng Phet, Thailand (1998-2002 and 2004-2007).

75 ppines (1), Sierra Leone (11), Tanzania (5), Thailand (2), Uganda (9), and Zimbabwe (15).

76 The RV144 HIV-1 vaccine trial (Thailand, 2003 to 2009), using immunogens genetically ma

77 om 2008 to 2010), and Wang Pha, northwestern Thailand (2009-2010), patients with uncomplicated falcip

78 search Council used the Bangkok Declaration, Thailand, 2009, as a guideline for their food compositio

79 5 635 travellers; 70 million residents), and Thailand (29 241 travellers; 59 million residents).

80 sites were 12.7% (2.2-33.0) in northeastern Thailand, 38.2% (15.9-60.5) in western Cambodia, 73.4% (

81 17,291 cases) data, we show that in Bangkok, Thailand, 60% of dengue cases living <200 meters apart c

82 ger female predominance (91%) in the US than Thailand (64%).

83 ected in 65 of 88 isolates from northeastern Thailand, 86 of 111 isolates from southern Laos, and 14

84 ], Brazil [8.7- 9.7], Chile [8.84-10.0], and Thailand [9.1-10.0]; there was perfect agreement between

85 ntify mortality due to seasonal influenza in Thailand, a tropical middle-income country.

86 eillance) and in 127 asymptomatic persons in Thailand (active surveillance).

87 rt, hepatitis B coinfection, and residing in Thailand (all P <= .03).

88 culture-confirmed melioidosis patients from Thailand along with 188 healthy donors from Thailand and

89 f 492 patients with P. vivax infections from Thailand and 476 patients (162 with concurrent falciparu

90 Thailand along with 188 healthy donors from Thailand and 90 healthy donors from the United States as

91 n Myanmar, and in relevant border regions in Thailand and Bangladesh, between January, 2013, and Sept

92 n longitudinal clinical cohorts conducted in Thailand and Brazil and identified candidate serological

93 s of dengue burden corresponding to those in Thailand and Brazil, respectively, to determine vaccine

94 All 46 MDR M. tuberculosis genomes from both Thailand and California were highly related, with a medi

95 n outbreak of tuberculosis among refugees in Thailand and consecutive cases within California.

96 In Thailand and Cote d'Ivoire, focusing treatment only on F

97 solved phylogenetic trees using genomes from Thailand and elsewhere to estimate when Zika virus was f

98 men (MSM) and transgender women, in Bangkok, Thailand and Harlem, New York, U.S.

99 men (MSM) and transgender women, in Bangkok, Thailand and Harlem, New York.

100 of intrahepatic cholangiocarcinoma (ICC) in Thailand and identify the prognostic factors for all-cau

101 der between eastern Myanmar and northwestern Thailand and in western Cambodia.

102 nics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-pho

103 arose in western Cambodia and then spread to Thailand and Laos, outcompeting other parasites and acqu

104 ed from HIV-exposed children in hospitals in Thailand and mailed to the Faculty of Associated Medical

105 Particularly in Thailand and most neighbouring low-income countries, scr

106 Although the disease is more prevalent in Thailand and northern Australia, sporadic cases may be e

107 ria pseudomallei, is endemic in northeastern Thailand and Northern Australia.

108 ll subsets in dengue patients from India and Thailand and show that these cells expand massively and

109 ients and 21 control subjects from Northeast Thailand and studied immune parameters in the context of

110 uous maps of alpha-thalassaemia mutations in Thailand and sub-national estimates of the number of new

111 (such as central, eastern, and northeastern Thailand and the Ayeyarwady Delta), where narrowing yiel

112 tients with anti-IFN-gamma autoantibodies in Thailand and the United States had distinct demographic

113 e most common nontuberculous mycobacteria in Thailand and the United States, respectively.

114 only isolated nontuberculous mycobacteria in Thailand and the US, respectively.

115 ruited from six public primary care units in Thailand and three primary care clinics and one outpatie

116 ates: Brazil, Mexico, Singapore, Taiwan, and Thailand and to ILI case count data from the United Stat

117 tients with anti-IFN-gamma autoantibodies in Thailand and US had distinct demographic and clinical fe

118 e countries (Indonesia, Malaysia, Singapore, Thailand and Vietnam) had guidelines for influenza vacci

119 producing countries (China, India, Malaysia, Thailand and Vietnam) were newly established to discrimi

120 In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most

121 Trial Centre at Mahidol University, Bangkok, Thailand and was divided into two parts.

122 riraj Hospital, Mahidol University, Bangkok, Thailand) and profiled.

123 .7% versus SE0 in Egypt, 22.0% versus ST0 in Thailand, and 13.1% versus SC0 in Cote d'Ivoire.

124 e Gambia, Kenya, Mali, South Africa, Zambia, Thailand, and Bangladesh), through 32 on-site courses an

125 bo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of geneticall

126 sing blood from water buffalo in Vietnam and Thailand, and goats in Zambia.

127 uman and fish ST283 isolates from Singapore, Thailand, and Hong Kong.

128 nal, prospective study in the United States, Thailand, and Kenya.

129 ctive, observational study in United States, Thailand, and Kenya.

130 to Leishmania enrietti, with cases in Ghana, Thailand, and Martinique; other relatives infect Austral

131 rrent fires with the most in Laos, Cambodia, Thailand, and Myanmar.

132 CD4 count, age >35 years, birth in northern Thailand, and positive anti-hepatitis C virus serology.

133 ase 3 trial was done at 36 centres in China, Thailand, and South Korea.

134 in the reference scenario, including Japan, Thailand, and Spain, were forecasted to have population

135 ssian Federation, South Africa, South Korea, Thailand, and Taiwan.

136 nducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines.

137 icacy by using 69 FAW specimens from Taiwan, Thailand, and the United States, with a 96% success rate

138 ion-making in four basins in Brazil, Mexico, Thailand, and the United States.

139 ls from Brazil, Ecuador, Peru, South Africa, Thailand, and the USA were enrolled into an open-label P

140 n Argentina, Brazil, South Africa, Tanzania, Thailand, and the USA.

141 ites in Brazil, Ecuador, Peru, South Africa, Thailand, and the USA.

142 We included participants from Vietnam, Thailand, and Uganda.

143 In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy

144 aso, Cameroon, Cote d'Ivoire, Senegal, Togo, Thailand, and Vietnam to assess virological failure and

145 Asia (Indonesia, Malaysia, the Philippines, Thailand, and Vietnam) from June 2011 through December 2

146 7 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falcipar

147 ng 15 post-trafficking services in Cambodia, Thailand, and Vietnam.

148 desh, the Gambia, Kenya, Mali, South Africa, Thailand, and Zambia).

149 desh, The Gambia, Kenya, Mali, South Africa, Thailand, and Zambia.

150 ru, and one each in Brazil, Kenya, Tanzania, Thailand, and Zimbabwe).

151 valence and mortality attributable to MDR in Thailand are high.

152 n be probably explained by the popularity of Thailand as a vacation destination characterized by sex

153 ani, is more closely related to cytoforms in Thailand, as are populations from Taiwan previously trea

154 stigational sites in China, South Korea, and Thailand, Asian patients, aged 18 years or older, with A

155 Africa in the mid-1970s, was introduced into Thailand between 1979 and 1982, and began expanding ther

156 capillariasis at Siriraj Hospital, Bangkok, Thailand between 2001- 2013.

157 and Treatment observational cohort study in Thailand between 2002 and 2010 were included.

158 ica, Mexico, the Philippines, Singapore, and Thailand between February 2010 and August 2011.

159 s delayed parasite clearance in the Cambodia-Thailand border area raises a serious concern.

160 year-long observational cohorts conducted in Thailand, Brazil and the Solomon Islands and antibody re

161 In the upper Gulf of Thailand, Bryde's whales, which feed on small fish speci

162 This regimen is used in Thailand but is associated with side-effects and poor ad

163 are associated with substantial mortality in Thailand, but evidence for the strong relationship betwe

164 nized, consists of three distinct species in Thailand: C. volvulus s.s., C. occultus sp. nov., and C.

165 m or mixed species malaria at seven sites in Thailand, Cambodia, and Vietnam were randomly assigned t

166 hydroartemisinin-piperaquine was observed in Thailand, Cambodia, and Vietnam.

167 ndomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were a

168 cratic Republic of Congo to 7.0 hours at the Thailand-Cambodia border.

169 95% of infections in Viet Nam, Cambodia, and Thailand), China, and West and Central Africa, mainly du

170 and apply it to 359 administrative units in Thailand, Colombia, Brazil and Mexico.

171 lus ribavirin was dominant or cost-saving in Thailand compared to a palliative care.

172 In Thailand, compared with pooled real-time PCR, RealAmp de

173 longan, one of the major processed fruits in Thailand, contain several bioactive compounds.

174 The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSV

175 es (Kenya, Burkina Faso, Mali, Cambodia, and Thailand) detected population genetic differences betwee

176 -CMV infection at Siriraj Hospital (Bangkok, Thailand) during 2008-2017.

177 peat infections to pertussis epidemiology in Thailand following a pronounced increase in vaccine upta

178 abases of nine public hospitals in northeast Thailand from 2004 to 2010, and linked these with the na

179 s provided by the National AIDS Programme in Thailand from 2007.

180 ess than 100/muL treated at an HIV clinic in Thailand from June 2010 through June 2012.

181 behavioural risk factors in MSM in Bangkok, Thailand, from 2006 to 2013.

182 In 2011, Thailand had the highest combined reported rate of vacci

183 We show that Thailand has been the source of viral dispersal to most

184 The use of stone tools by macaques in Thailand has reduced the size and population density of

185 Northeastern Thailand has the highest incidence of CCA, and there is

186 Studies on Mycoplasma pneumoniae in Thailand have focused on urban centers and have not incl

187 idosis, is highly conserved in isolates from Thailand; however, the LPSs isolated from other, related

188 al-acquired infection due to MDR bacteria in Thailand in 2010 represented excess mortality caused by

189 ll be born with severe alpha-thalassaemia in Thailand in 2020, which is considerably higher than prev

190 sessed the performance of 17 laboratories in Thailand in analysing mandatory nutrients in salted, fri

191 Centralised Zika virus surveillance began in Thailand in January, 2016.

192 The central role of Thailand in the global spread of CRF01_AE can be probabl

193 with LAIV is likely to be cost-effective in Thailand in the short term, though the long-term consequ

194 in 2018, followed by a workshop in Bangkok, Thailand, in 2019, concluded that there are few birth co

195 contexts, including many western countries, Thailand, India, the Democratic Republic of Congo, Kenya

196 sociated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi.

197 The disease burden of patients with ICC in Thailand is significant with the incidence rate of 14.6

198 lion-year-old Proganochelys from Germany and Thailand, it retains marginal teeth and lacks a carapace

199 was introduced to the Maela refugee camp in Thailand, July 2004.The effect of the length of gestatio

200 Lower Mekong River Basin countries including Thailand, Lao PDR, Vietnam and Cambodia.

201 of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count, 188 cells/microL; mea

202 s, and private physician offices in the USA, Thailand, Mexico, Argentina, and Australia.

203 , Vietnam, and Laos and the other in western Thailand, Myanmar, and China--with no overlap.

204 o address the risk of transmission along the Thailand-Myanmar border and represents a promising tool

205 modalities of malaria transmission along the Thailand-Myanmar border are poorly understood.

206 ria in clinical studies in Myanmar or on the Thailand-Myanmar border had recurrent Plasmodium vivax m

207 yment of mefloquine-artesunate (MAS3) on the Thailand-Myanmar border has led to a sustained reduction

208 P. vivax infections in 1299 patients on the Thailand-Myanmar border observed over 1000 patient follo

209 s with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloro

210 artemisinin-based combination (MAS3) on the Thailand-Myanmar border.

211 = 6,666 pregnancies, six sites) and one from Thailand (n = 23,952).

212 LRs) were evaluated for VAD in children from Thailand (n = 37) and Zambia (n = 128).

213 6), Malaysia (n = 10), Myanmar (n = 6), and Thailand (n = 8).

214 ithin Asia (Vietnam, n = 11; Bhutan, n = 12; Thailand, n = 1; Cambodia, n = 1) and two outside of Asi

215 eas in Puerto Rico, Columbia, Singapore, and Thailand (NCT01511250).

216 areas in Brazil, Costa Rica, Indonesia, and Thailand on carbon storage in forests.

217 hic analysis indicated that GI-a diverged in Thailand or Cambodia and has remained confined to tropic

218 CI; 1.2-1.4), living in the northern part of Thailand (OR = 1.5, 95% CI; 1.3-1.8) and presence of com

219 ars in posttrafficking services in Cambodia, Thailand, or Vietnam, which along with Laos, Myanmar, an

220 If PrEP were to be implemented in Thailand, our findings show that its uptake could be con

221 o prevent influenza transmission in Bangkok, Thailand, over 34 months between 2008 and 2011, we estim

222 iparum isolates from five sites in Northwest Thailand, over the period of a rapid increase in the eme

223 a autoantibody levels decreased over time in Thailand (P < .001) and the United States (P = .017), wi

224 Skin infections were more common in Thailand (P = .001), whereas bone (P < .0001), lung (P =

225 a autoantibody levels decreased over time in Thailand (P<0.001) and the US (P=0.017), as well as with

226 Skin infections were more common in Thailand (P=0.001) whereas bone (P<0.0001), lung (P=0.00

227 n acute and recurrent infections (P = .48 in Thailand, P = .08 in Indonesia).

228 outbreak in 2014 in Ubon Ratchatani, Eastern Thailand, parasites from 101 patients with falciparum ma

229 in HIV 010 (RV254/SEARCH010) study (Bangkok, Thailand) participants at weeks 12 and 24 following the

230 enrolled from 8 sites in the United States, Thailand, Peru, and South Africa with mean age of 31.1 y

231 ence = 14.7%; 45,000 patients treated/year), Thailand (prevalence = 2.2%; 1,000 patients treated/year

232 ive population-based surveillance in 2 rural Thailand provinces during 2008-2011.

233 m infections has been conducted in two rural Thailand provinces for >7 years.

234 In the 1990s, reports from northern Thailand raised a troubling observation; some scrub typh

235 for persons born in Colombia, Malaysia, and Thailand, ranging from 8%-13%.

236 related but distinct allelic variants within Thailand, rather than the occurrence of a single outbrea

237 , Egypt, France, Germany, India, Norway, and Thailand) recruited participants who had reliable inform

238 icularis) in Khao Sam Roi Yot National Park, Thailand, reduces prey size and prey abundance, with mor

239 Thailand Research Fund, the Melioidosis Research Center,

240 or countries' (including Uganda, Croatia and Thailand): researchers from these countries appear almos

241 7 positive cases were detected in India and Thailand, respectively, via PCR.

242 serves created by 23 separate communities in Thailand's Salween basin have markedly increased fish ri

243 aureus isolates from unselected patients in Thailand showed that 10 (4.1%) were actually Staphylococ

244 ctions suggest persistent circulation within Thailand since at least 2002.

245 es in five countries/states: Mexico, Brazil, Thailand, Singapore and Taiwan.

246 g Taiwan, Hong Kong, China, India, Malaysia, Thailand, Singapore, Indonesia, Philippines, Japan, and

247 t-line virologic failure in individuals from Thailand, South Africa, India, Malawi, Tanzania.

248 lciparum isolates from Myanmar, northeastern Thailand, southern Laos, and western Cambodia for PfKelc

249 n 37 participants (RV254/SEARCH010, Bangkok, Thailand) stratified by Fiebig stage (Fiebig stage I [FI

250 A study in Thailand suggests condom machines may provide comfortabl

251 infection were recruited from study sites in Thailand, Tanzania, Uganda, and Kenya with high HIV-1 pr

252 ts that PrEP was more effective among MSM in Thailand than in the U.S. as a result of more fully cove

253 ts that PrEP was more effective among MSM in Thailand than in the United States as a result of more f

254 acaque stone tools from Piak Nam Yai Island, Thailand, that had been collected following behavioural

255 In Thailand, the cumulative incidence of gametocytemia betw

256 igh in countries as diverse as China, Kenya, Thailand, the UK, and the USA, with substantial disparit

257 ed in adults aged 18-64 years at 42 sites in Thailand, the United States, and Argentina.

258 Within Thailand these chains quickly mix, and by the next dengu

259 tional Institute of Child Health in Bangkok, Thailand, this article provides the authors' perspective

260 ntries, ranging from 3.37% (3.06 to 3.63) in Thailand to 11.00% (9.29 to 12.47) in China.

261 he world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the

262 hase 2, open-label study at three centers in Thailand to assess the antimalarial efficacy, safety, an

263 ia, Malaysia, Pakistan, the Philippines, and Thailand to discuss common challenges to the burden pose

264 th or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at pos

265 We use a variety of different datasets from Thailand to study not only the extremes of micro and mac

266 2 independent ethnic groups relocating from Thailand to the United States.

267 wo independent ethnic groups relocating from Thailand to the United States.

268 opia, France, Ghana, Indonesia, Japan, Peru, Thailand, Turkey, and Vietnam), representing diverse geo

269 V from ten hospital clinics in South Africa, Thailand, Uganda, and the USA.

270 prospectively for 10 weeks during trials in Thailand, Uganda, Malawi, and South Africa.

271 , Australia, Denmark, Greece, Mexico, Spain, Thailand, UK, and the USA over five influenza seasons fr

272 Kong, Israel, Italy, Russia, Spain, Taiwan, Thailand, UK, and USA).

273 , Japan, South Korea, Spain, Sweden, Taiwan, Thailand, UK, and USA.

274 e results were then combined with those from Thailand using aggregated data meta-analysis with a rand

275 cruited patients from 38 sites across China, Thailand, Vietnam, Singapore, and Malaysia, who were chr

276 Thailand was co-cultured with B. pseudomallei and produc

277 Thailand was excluded from incidence analyses because of

278 mic data on 88 P. vivax samples from western Thailand, we identified pvmdr1 amplification in 17 isola

279 ilar data for Malaysia, the Philippines, and Thailand were also extracted but were incomplete.

280 m an additional 135 febrile individuals from Thailand were also used.

281 ma autoantibodies at Srinagarind Hospital in Thailand were collected at annual follow-up visits (medi

282 (CPO) production by a wet extraction mill in Thailand were developed.

283 viverrini eggs, of residents in Northeastern Thailand were investigated for associations among infect

284 han half of diabetic melioidosis patients in Thailand were prescribed glibenclamide.

285 esma bunius) cultivars grown in Northeastern Thailand were quantified using HPLC analysis and the ant

286 y eye from a tertiary eye center in northern Thailand were randomized to receive transdermal androgen

287 n four sites in Africa and 14 communities in Thailand were randomly allocated in matched pairs to rec

288 amma autoantibodies at Srinagarind Hospital, Thailand, were collected annually (median follow-up dura

289 nant women in Bangalore, India, and Bangkok, Thailand, were randomly assigned (1:1) to receive 200 mu

290 is information comes from Phra Thong Island, Thailand, where a sequence of four stacked sandsheets se

291 oolchildren in the Mueang Rayong district of Thailand, where a similar study had been conducted in 19

292 1_AE originated in Africa and then passed to Thailand, where it established a major epidemic.

293 sier to achieve in regions such as China and Thailand, where the epidemic is more recent and the viru

294 _AE is the predominant circulating strain in Thailand, where the RV144 trial took place.

295 rget children for dengue mass vaccination in Thailand, whereas young adults should be targeted in Bra

296 such as Botswana, Brazil, South Africa, and Thailand, which have already established viral load prog

297 d mononuclear cells (PBMCs) from children in Thailand with acute primary or secondary DENV-1 infectio

298 >/=15 years) from five centres in northeast Thailand with culture-confirmed melioidosis who had rece

299 ant (LT) cases in several regions, including Thailand, with genotype 3 being a predominant genotype.

300 Despite its multiple challenges, MSM in Thailand would be willing to take PrEP, even if they had